# AMG 102 and Avastin for Recurrent Malignant Glioma

> **NCT01113398** · PHASE2 · COMPLETED · sponsor: **Katy Peters** · enrollment: 36 (actual)

## Conditions studied

- Glioblastoma Multiforme
- Gliosarcoma

## Interventions

- **DRUG:** AMG 102
- **DRUG:** Avastin

## Key facts

- **NCT ID:** NCT01113398
- **Lead sponsor:** Katy Peters
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2014-11
- **Final completion:** 2015-09
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2015-12-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01113398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01113398, "AMG 102 and Avastin for Recurrent Malignant Glioma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01113398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*